Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Histogen Inc
Healthcare
P/NCAV
0.22x
Ticker
HSTO
Exchange
Over The Counter
Country
United States
Close
0.35 $
Mkt Cap
1.1M $
EV
-3.4M $
NCAV Burn Rate
55.6%
Current Ratio
4.05
Debt/Equity
0.0
EV/REV
-0.92x
EV/EBIT
0.3x
EV/FCF
0.4x
Dilution
64.3% p.A
Total Net Income
-182.9M $
Cheapness
99.0%
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average